PRESCRIBING: BONA FIDE RELATIONSHIP                                               H.B. 5678 (S-4):

                                                                                                    SUMMARY OF BILL

                                                                                                  ON THIRD READING

House Bill 5678 (Substitute S-4 as reported by the Committee of the Whole)

Sponsor:  Representative Bronna Kahle

House Committee:  Health Policy

Senate Committee:  Health Policy

CONTENT

The bill would amend the Public Health Code to revise the date on which a prescriber will be prohibited from prescribing a Schedule 2 to 5 controlled substance unless the prescriber is in a bona-fide prescriber-patient relationship with the patient.

Section 7303a of the Code sets forth requirements for a licensed prescriber who prescribes a controlled substance. Public Act 247 of 2017, which took effect on December 27, 2017, amended the section to prohibit a licensed prescriber, beginning March 31, 2018, from prescribing a Schedule 2 to 5 controlled substance unless the prescriber is in a bona fide prescriber-patient relationship with the patient for whom the controlled substance is being prescribed, except as otherwise provided by rules promulgated by the Department of Licensing and Regulatory Affairs (LARA), in consultation with certain State medical boards.

Under the bill, the prohibition would take effect on March 31, 2019 or, if LARA promulgated rules before March 31, 2019, the date on which the rules were promulgated. 

MCL 333.7303a                                                       Legislative Analyst:  Stephen Jackson

FISCAL IMPACT

The bill would have no fiscal impact on State or local government.

Date Completed:  3-22-18                                         Fiscal Analyst:  Elizabeth Raczkowski

This analysis was prepared by nonpartisan Senate staff for use by the Senate in its deliberations and does not constitute an official statement of legislative intent.